In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report), with a price target of $10.00. The company’s shares opened today at $2.27.
McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inmune Bio, and Indaptus Therapeutics. According to TipRanks, McCarthy has an average return of -15.0% and a 30.41% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Acurx Pharmaceuticals with a $11.00 average price target, implying a 384.58% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.
Based on Acurx Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $5.11 million. In comparison, last year the company had a GAAP net loss of $3.26 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acurx Pharmaceuticals (ACXP) Company Description:
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
Read More on ACXP:
- Acurx reports results from meeting with FDA regarding ibezapolstat
- Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update
- Acurx presents ibezapolstat Phase 2 clinical trial results in CDI
- Acurx price target lowered to $12 from $14 at H.C. Wainwright
- Acurx files common stock offering, no amount given
